Aktis signs $1.1B cancer radiopharmaceutical deal with Eli Lilly


Eli Lilly and Co. is building on its strength in the field to advance the radiopharmaceutical revolution through a deal that could bring Aktis Oncology Inc. $1.1 billion. The two plan to develop radiopharmaceuticals that target cancer. Privately held Aktis also received $60 million in cash and equity investment. Significant funding will come from preclinical, clinical, regulatory, commercial milestones and tiered royalties. Lily will choose the target.

biological world Transactions and M&A cancer



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top